PURPOSE: It has been suggested that PTEN, a negative regulator of PI3K/AKT signaling, is involved in tumor sensitivity to trastuzumab. We investigated the association between tumor PTEN protein expression and disease-free survival (DFS) of patients randomly assigned to receive chemotherapy alone (arm A) or chemotherapy with sequential (arm B) or concurrent trastuzumab (arm C) in the phase III early-stage human epidermal growth factor receptor 2 (HER2) -positivetrial-North Central Cancer Treatment Group (NCCTG) N9831. PATIENTS AND METHODS: The intensity and percentage of invasive cells with cytoplasmic PTEN staining were determined in tissue microarray sections containing three cores per block (n = 1,286) or in whole tissue sections (WS; n = 516) by using standard immunohistochemistry (138G6 monoclonal antibody). Tumors were considered positive for PTEN (PTEN-positive) if any core or WS had any invasive cells with ≥ 1+ staining. Median follow-up was 6.0 years. RESULTS: Of 1,802 patients included in this analysis (of 3,505 patients registered to N9831), 1,342 (74%) had PTEN-positive tumors. PTEN positivity was associated with hormone receptor negativity (χ(2) P < .001) and nodal positivity (χ(2) P = .04). PTEN did not have an impact on DFS within the various arms. Comparing DFS of arm C to arm A, patients with PTEN-positive and PTEN-negative tumors had hazard ratios (HRs) of 0.65 (P = .003) and 0.47 (P = .005), respectively (interaction P = .16). For arm B versus arm A, patients with PTEN-positive and PTEN-negative tumors had HRs of 0.70 (P = .009) and 0.85 (P = .44), respectively (interaction P = .47). CONCLUSION: In contrast to selected preclinical and limited clinical studies suggesting a decrease in trastuzumab sensitivity in patients with PTEN-negative tumors, our data show benefit of adjuvant trastuzumab for patients with HER2-positive breast cancer, independent of tumor PTEN status.
RCT Entities:
PURPOSE: It has been suggested that PTEN, a negative regulator of PI3K/AKT signaling, is involved in tumor sensitivity to trastuzumab. We investigated the association between tumorPTEN protein expression and disease-free survival (DFS) of patients randomly assigned to receive chemotherapy alone (arm A) or chemotherapy with sequential (arm B) or concurrent trastuzumab (arm C) in the phase III early-stage humanepidermal growth factor receptor 2 (HER2) -positive trial-North Central Cancer Treatment Group (NCCTG) N9831. PATIENTS AND METHODS: The intensity and percentage of invasive cells with cytoplasmic PTEN staining were determined in tissue microarray sections containing three cores per block (n = 1,286) or in whole tissue sections (WS; n = 516) by using standard immunohistochemistry (138G6 monoclonal antibody). Tumors were considered positive for PTEN (PTEN-positive) if any core or WS had any invasive cells with ≥ 1+ staining. Median follow-up was 6.0 years. RESULTS: Of 1,802 patients included in this analysis (of 3,505 patients registered to N9831), 1,342 (74%) had PTEN-positive tumors. PTEN positivity was associated with hormone receptor negativity (χ(2) P < .001) and nodal positivity (χ(2) P = .04). PTEN did not have an impact on DFS within the various arms. Comparing DFS of arm C to arm A, patients with PTEN-positive and PTEN-negative tumors had hazard ratios (HRs) of 0.65 (P = .003) and 0.47 (P = .005), respectively (interaction P = .16). For arm B versus arm A, patients with PTEN-positive and PTEN-negative tumors had HRs of 0.70 (P = .009) and 0.85 (P = .44), respectively (interaction P = .47). CONCLUSION: In contrast to selected preclinical and limited clinical studies suggesting a decrease in trastuzumab sensitivity in patients with PTEN-negative tumors, our data show benefit of adjuvant trastuzumab for patients with HER2-positive breast cancer, independent of tumorPTEN status.
Authors: Neil A O'Brien; Brigid C Browne; Lucy Chow; Yuhua Wang; Charles Ginther; Jane Arboleda; Michael J Duffy; John Crown; Norma O'Donovan; Dennis J Slamon Journal: Mol Cancer Ther Date: 2010-05-25 Impact factor: 6.261
Authors: Ana M Gonzalez-Angulo; Jaime Ferrer-Lozano; Katherine Stemke-Hale; Aysegul Sahin; Shuying Liu; Juan A Barrera; Octavio Burgues; Ana M Lluch; Huiqin Chen; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam Journal: Mol Cancer Ther Date: 2011-04-13 Impact factor: 6.261
Authors: Alessandra Fabi; G Metro; A Di Benedetto; C Nisticò; P Vici; E Melucci; B Antoniani; L Perracchio; I Sperduti; M Milella; F Cognetti; M Mottolese Journal: Oncology Date: 2010-04-13 Impact factor: 2.935
Authors: Rita A Sakr; Violetta Barbashina; Mary Morrogh; Sarat Chandarlapaty; Victor P Andrade; Crispinita D Arroyo; Narciso Olvera; Tari A King Journal: Appl Immunohistochem Mol Morphol Date: 2010-07
Authors: Gizeh Pérez-Tenorio; Liza Alkhori; Birgit Olsson; Marie Ahnström Waltersson; Bo Nordenskjöld; Lars Erik Rutqvist; Lambert Skoog; Olle Stål Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: S Gori; A Sidoni; M Colozza; I Ferri; M G Mameli; D Fenocchio; L Stocchi; J Foglietta; V Ludovini; E Minenza; V De Angelis; L Crinò Journal: Ann Oncol Date: 2009-02-02 Impact factor: 32.976
Authors: Dana Faratian; Alexey Goltsov; Galina Lebedeva; Anatoly Sorokin; Stuart Moodie; Peter Mullen; Charlene Kay; In Hwa Um; Simon Langdon; Igor Goryanin; David J Harrison Journal: Cancer Res Date: 2009-07-28 Impact factor: 12.701
Authors: T Fujita; H Doihara; K Kawasaki; D Takabatake; H Takahashi; K Washio; K Tsukuda; Y Ogasawara; N Shimizu Journal: Br J Cancer Date: 2006-01-30 Impact factor: 7.640
Authors: Howard M Stern; Humphrey Gardner; Tomasz Burzykowski; Wafaa Elatre; Carol O'Brien; Mark R Lackner; Gary A Pestano; Angela Santiago; Ivonne Villalobos; Wolfgang Eiermann; Tadeusz Pienkowski; Miguel Martin; Nicholas Robert; John Crown; Paolo Nuciforo; Valerie Bee; John Mackey; Dennis J Slamon; Michael F Press Journal: Clin Cancer Res Date: 2015-02-03 Impact factor: 12.531
Authors: Alexandre A B A da Costa; Felipe D'Almeida Costa; Adriana R Ribeiro; Andréia P Guimarães; Ludmila T Chinen; Clóvis A P Lopes; Vladmir C C de Lima Journal: Int J Clin Oncol Date: 2014-05-27 Impact factor: 3.402
Authors: P G Nuciforo; C Aura; E Holmes; L Prudkin; J Jimenez; P Martinez; H Ameels; L de la Peña; C Ellis; H Eidtmann; M J Piccart-Gebhart; M Scaltriti; J Baselga Journal: Ann Oncol Date: 2015-04-07 Impact factor: 32.976
Authors: Manuel Valdivieso; Benjamin W Corn; Janet E Dancey; D Lawrence Wickerham; L Elise Horvath; Edith A Perez; Alison Urton; Walter M Cronin; Erica Field; Evonne Lackey; Charles D Blanke Journal: Semin Oncol Date: 2015-07-10 Impact factor: 4.929
Authors: Ciara C O'Sullivan; Ian Bradbury; Christine Campbell; Marc Spielmann; Edith A Perez; Heikki Joensuu; Joseph P Costantino; Suzette Delaloge; Priya Rastogi; Dimitrios Zardavas; Karla V Ballman; Eileen Holmes; Evandro de Azambuja; Martine Piccart-Gebhart; Jo Anne Zujewski; Richard D Gelber Journal: J Clin Oncol Date: 2015-06-22 Impact factor: 44.544
Authors: Mothaffar F Rimawi; Carmine De Angelis; Alejandro Contreras; Fresia Pareja; Felipe C Geyer; Kathleen A Burke; Sabrina Herrera; Tao Wang; Ingrid A Mayer; Andres Forero; Rita Nanda; Matthew P Goetz; Jenny C Chang; Ian E Krop; Antonio C Wolff; Anne C Pavlick; Suzanne A W Fuqua; Carolina Gutierrez; Susan G Hilsenbeck; Marilyn M Li; Britta Weigelt; Jorge S Reis-Filho; C Kent Osborne; Rachel Schiff Journal: Breast Cancer Res Treat Date: 2017-11-07 Impact factor: 4.872
Authors: Amylou C Dueck; Monica M Reinholz; Xochiquetzal J Geiger; Kathleen Tenner; Karla Ballman; Robert B Jenkins; Darren Riehle; Beiyun Chen; Ann E McCullough; Nancy E Davidson; Silvana Martino; George W Sledge; Peter A Kaufman; Leila A Kutteh; Julie Gralow; Lyndsay N Harris; James N Ingle; Wilma L Lingle; Edith A Perez Journal: Clin Cancer Res Date: 2013-08-21 Impact factor: 12.531